Avisi (Therapeutic Devices) key facts
as of Oct 2026- Developer of a nanotechnology-enabled glaucoma implant designed to lower intraocular pressure and slow vision loss in patients with open-angle glaucoma.
- Avisi (Therapeutic Devices) is valued at approximately $40.0M as of Oct 2026 (last reported valuation).
- It has raised $21.7M; the latest was Later Stage VC ($15.9M) in Feb 2026.
- Notable investors include US National Science Foundation, MedTech Innovator, Gaingels, Keiretsu Forum, VentureWell — 35 tracked in total.
- Status: Privately Held (backing).
Avisi (Therapeutic Devices)'s last reported valuation, Feb 2026. Nothing priced has surfaced since.
- ·The complete investor list: 35 names
- ·Watch Avisi (Therapeutic Devices): the Monday email on marks, rounds and moves
Avisi (Therapeutic Devices) funding rounds
No funding rounds for Avisi (Therapeutic Devices) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Avisi (Therapeutic Devices)
35+Membership and data by Private Market View
Avisi (Therapeutic Devices) valuation
Avisi (Therapeutic Devices)'s last reported valuation was $40 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.
Avisi (Therapeutic Devices) investors
35 investors are on record for Avisi (Therapeutic Devices), including US National Science Foundation, MedTech Innovator, Gaingels and Keiretsu Forum.
About Avisi (Therapeutic Devices)
Developer of a nanotechnology-enabled glaucoma implant designed to lower intraocular pressure and slow vision loss in patients with open-angle glaucoma. The company offers an ultrathin multichannel aqueous shunt made with advanced microfabrication and biocompatible materials, enabling ophthalmologists and glaucoma patients to achieve controlled fluid drainage and improved long-term eye health.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2017
- Employees
- 7
- Website
- avisitech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.